Page 4 - Edwin Kim News Today

email article The peanut-powder oral treatment Palforzia became the first FDA-approved immunotherapy for food allergy in late January 2020. The peanut (Arachis Hypogaea) allergen powder-dnfp is designed to desensitize peanut allergies in children and adolescents, and prevent potentially life-threatening reactions. Within 6 weeks of its approval for use in children, age 4-17 years, most of the U.S. shut down due to the pandemic, and it was widely agreed that the timing of the immunotherapy...

Milwaukee, Wisconsin (PRWEB) February 15, 2021 -- Research to be presented at the 2021 American Academy of Allergy, Asthma & Immunology (AAAAI) Virtual Annual

Ukko Secures $40 Million in Series B Funding Led by Leaps by Bayer to Overcome Food Allergies and Sensitivities Top industry leaders and venture firms unite behind Ukkos efforts to eliminate the worlds most prevalent food allergies and sensitivities, including peanuts and gluten News provided by Share this article Share this article PALO ALTO, Calif., TEL AVIV, Israel and LEVERKUSEN, Germany, Jan. 27, 2021 /PRNewswire/ -- Ukko, a biotech company with the mission to eliminate food allergies and ...